Search
for

    Glossary Trametinib

    medication that inhibits MEK protein to treat specific cancers

    Trametinib is a medication used to treat certain types of cancer, specifically melanoma with a BRAF V600E or V600K mutation. It works by inhibiting a protein called MEK, which is part of a pathway that helps cancer cells grow and divide. By blocking this protein, trametinib can slow down or stop the growth of cancer cells.

    Research 10 of 75

    1. Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib Journal of cutaneous medicine and surgery · 2016 · 10 citations
    2. Pustular Eruption in a Patient Treated With Trametinib Pediatric Dermatology · 2025
    3. Identifying the Target Cells and Mechanisms of Merkel Cell Polyomavirus Infection Cell Host & Microbe · 2016 · 133 citations
    4. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma 2016 · 32 citations
    5. Cutaneous reactions to targeted therapies in children with CNS tumors: A cross‐sectional study Pediatric Blood & Cancer · 2019 · 16 citations
    6. Dyad of infantile cutaneous and thymic Langerhans cell histiocytosis: Is it rare? Pediatric blood & cancer · 2023
    7. 645 MIG6 is MEK-regulated and affects EGF-induced migration in mutant NRAS melanoma Journal of Investigative Dermatology · 2016
    8. 696 MEK and BRAF inhibitors augment the production and accumulation of sebum in hamster sebocytes Journal of Investigative Dermatology · 2016
    9. Multimodal therapeutic approach for a severe case of kaposiform lymphangiomatosis from procedural interventions to targeted therapies Pediatric Blood & Cancer · 2024 · 1 citations
    10. Hydrogel-Forming Microneedles for Transdermal Drug Delivery Preprints.org · 2023 · 10 citations
    All research results →

    Learn

    — no results

    Try a deeper search in learn →

    Community

    — no results

    Try a deeper search in community →